Study Exploring the Supportive Effect of Acarbose in Weight Management
A 26-week, Double-blind, Randomized Study in Participants With Overweight or Obesity Investigating the Added Contribution of Acarbose in EMP16 on Efficacy, Safety and Tolerability
Sponsor: CTC Clinical Trial Consultants AB
Listed as NCT05934110, this PHASE2 trial focuses on Overweight or Obesity and remains ongoing. Sponsored by CTC Clinical Trial Consultants AB, it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Mar 2026 — Present [monthly]
Unknown PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2025 — Mar 2026 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 1 earlier version
-
Aug 2023 — Mar 2024 [monthly]
Recruiting PHASE2
First recorded
Apr 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CTC Clinical Trial Consultants AB
- Empros Pharma AB
For direct contact, visit the study record on ClinicalTrials.gov .